Table of Contents

1 Study Coverage

• 1.1 Hadron Therapy Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Hadron Therapy Market Size Growth Rate by Product
  • 1.4.2 Electron Beam
  • 1.4.3 Proton Beam
  • 1.4.4 Neutron Beam
  • 1.4.5 Carbon Ion Beam
  • 1.4.6 Alpha Particle Beam
  • 1.4.7 Beta Particle Beam
• 1.5 Market by End User
  • 1.5.1 Global Hadron Therapy Market Size Growth Rate by End User
  • 1.5.2 Pediatric Cancer
  • 1.5.3 Bone and Soft Tissue Cancer
  • 1.5.4 Prostate Cancer
  • 1.5.5 Lung Cancer
  • 1.5.6 Liver Cancer
  • 1.5.7 Eye Cancer
  • 1.5.8 Head & Neck Cancer
  • 1.5.9 Others Applications (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Hadron Therapy Market Size
  • 2.1.1 Global Hadron Therapy Revenue 2014-2025
  • 2.1.2 Global Hadron Therapy Sales 2014-2025
• 2.2 Hadron Therapy Growth Rate by Regions
  • 2.2.1 Global Hadron Therapy Sales by Regions
  • 2.2.2 Global Hadron Therapy Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Hadron Therapy Sales by Manufacturers
  • 3.1.1 Hadron Therapy Sales by Manufacturers
  • 3.1.2 Hadron Therapy Sales Market Share by Manufacturers
  • 3.1.3 Global Hadron Therapy Market Concentration Ratio (CR5 and HHI)
• 3.2 Hadron Therapy Revenue by Manufacturers
  • 3.2.1 Hadron Therapy Revenue by Manufacturers (2014-2019)
  • 3.2.2 Hadron Therapy Revenue Share by Manufacturers (2014-2019)
• 3.3 Hadron Therapy Price by Manufacturers
• 3.4 Hadron Therapy Manufacturing Base Distribution, Product Types
  • 3.4.1 Hadron Therapy Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Hadron Therapy Product Type
  • 3.4.3 Date of International Manufacturers Enter into Hadron Therapy Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Hadron Therapy Sales by Product
• 4.2 Global Hadron Therapy Revenue by Product
• 4.3 Hadron Therapy Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Hadron Therapy Breakdown Data by End User

6 North America

• 6.1 North America Hadron Therapy by Countries
  • 6.1.1 North America Hadron Therapy Sales by Countries
  • 6.1.2 North America Hadron Therapy Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Hadron Therapy by Product
• 6.3 North America Hadron Therapy by End User

7 Europe

• 7.1 Europe Hadron Therapy by Countries
  • 7.1.1 Europe Hadron Therapy Sales by Countries
  • 7.1.2 Europe Hadron Therapy Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Hadron Therapy by Product
• 7.3 Europe Hadron Therapy by End User

8 Asia Pacific

• 8.1 Asia Pacific Hadron Therapy by Countries
  • 8.1.1 Asia Pacific Hadron Therapy Sales by Countries
  • 8.1.2 Asia Pacific Hadron Therapy Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Hadron Therapy by Product
• 8.3 Asia Pacific Hadron Therapy by End User

9 Central & South America

• 9.1 Central & South America Hadron Therapy by Countries
  • 9.1.1 Central & South America Hadron Therapy Sales by Countries
  • 9.1.2 Central & South America Hadron Therapy Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Hadron Therapy by Product
• 9.3 Central & South America Hadron Therapy by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Hadron Therapy by Countries
  • 10.1.1 Middle East and Africa Hadron Therapy Sales by Countries
  • 10.1.2 Middle East and Africa Hadron Therapy Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Hadron Therapy by Product
• 10.3 Middle East and Africa Hadron Therapy by End User

11 Company Profiles

• 11.1 Koninklijke Philips N.V.
  • 11.1.1 Koninklijke Philips N.V. Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Koninklijke Philips N.V. Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Koninklijke Philips N.V. Hadron Therapy Products Offered
  • 11.1.5 Koninklijke Philips N.V. Recent Development
• 11.2 Advanced Oncotherapy
  • 11.2.1 Advanced Oncotherapy Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Advanced Oncotherapy Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Advanced Oncotherapy Hadron Therapy Products Offered
  • 11.2.5 Advanced Oncotherapy Recent Development
• 11.3 Varian Medical Systems
  • 11.3.1 Varian Medical Systems Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Varian Medical Systems Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Varian Medical Systems Hadron Therapy Products Offered
  • 11.3.5 Varian Medical Systems Recent Development
• 11.4 Optivus Proton Therapy
  • 11.4.1 Optivus Proton Therapy Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Optivus Proton Therapy Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Optivus Proton Therapy Hadron Therapy Products Offered
  • 11.4.5 Optivus Proton Therapy Recent Development
• 11.5 Hitachi, Ltd.
  • 11.5.1 Hitachi, Ltd. Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Hitachi, Ltd. Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Hitachi, Ltd. Hadron Therapy Products Offered
  • 11.5.5 Hitachi, Ltd. Recent Development
• 11.6 Mevion Medical Systems
  • 11.6.1 Mevion Medical Systems Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Mevion Medical Systems Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Mevion Medical Systems Hadron Therapy Products Offered
  • 11.6.5 Mevion Medical Systems Recent Development
• 11.7 ProTom International
  • 11.7.1 ProTom International Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 ProTom International Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 ProTom International Hadron Therapy Products Offered
  • 11.7.5 ProTom International Recent Development
• 11.8 Mitsubishi Electric Corporation
  • 11.8.1 Mitsubishi Electric Corporation Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Mitsubishi Electric Corporation Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Mitsubishi Electric Corporation Hadron Therapy Products Offered
  • 11.8.5 Mitsubishi Electric Corporation Recent Development
• 11.9 Sumitomo Corporation
  • 11.9.1 Sumitomo Corporation Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Sumitomo Corporation Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Sumitomo Corporation Hadron Therapy Products Offered
  • 11.9.5 Sumitomo Corporation Recent Development
• 11.10 ProNova Solutions, LLC
  • 11.10.1 ProNova Solutions, LLC Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 ProNova Solutions, LLC Hadron Therapy Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 ProNova Solutions, LLC Hadron Therapy Products Offered
  • 11.10.5 ProNova Solutions, LLC Recent Development

12 Future Forecast

• 12.1 Hadron Therapy Market Forecast by Regions
  • 12.1.1 Global Hadron Therapy Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Hadron Therapy Revenue Forecast by Regions 2019-2025
• 12.2 Hadron Therapy Market Forecast by Product
  • 12.2.1 Global Hadron Therapy Sales Forecast by Product 2019-2025
  • 12.2.2 Global Hadron Therapy Revenue Forecast by Product 2019-2025
• 12.3 Hadron Therapy Market Forecast by End User
• 12.4 North America Hadron Therapy Forecast
• 12.5 Europe Hadron Therapy Forecast
• 12.6 Asia Pacific Hadron Therapy Forecast
• 12.7 Central & South America Hadron Therapy Forecast
• 12.8 Middle East and Africa Hadron Therapy Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Hadron Therapy Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Radiation therapy is the medical use of ionizing radiation to treat cancer. In conventional radiation therapy, beams of X rays (high energy photons) are produced by accelerated electrons and then delivered to the patient to destroy tumour cells. Using crossing beams from many angles, radiation oncologists irradiate the tumour target while trying to spare the surrounding normal tissues. Inevitably some radiation dose is always deposited in the healthy tissues.
When the irradiating beams are made of charged particles (protons and other ions, such as carbon), radiation therapy is called hadrontherapy. The strength of hadrontherapy lies in the unique physical and radiobiological properties of these particles; they can penetrate the tissues with little diffusion and deposit the maximum energy just before stopping. This allows a precise definition of the specific region to be irradiated. The peaked shape of the hadron energy deposition is called Bragg peak and has become the symbol of hadrontherapy. With the use of hadrons the tumour can be irradiated while the damage to healthy tissues is less than with X-rays.
The idea of using protons for cancer treatment was first proposed in 1946 by the physicist Robert Wilson, who later became the founder and first director of the Fermi National Accelerator Laboratory (Fermilab) near Chicago. The first patients were treated in the 1950s in nuclear physics research facilities by means of non-dedicated accelerators. Initially, the clinical applications were limited to few parts of the body, as accelerators were not powerful enough to allow protons to penetrate deep in the tissues.
In the late 1970s improvements in accelerator technology, coupled with advances in medical imaging and computing, made proton therapy a viable option for routine medical applications. However, it has only been since the beginning of the 1990s that proton facilities have been established in clinical settings, the first one being in Loma Linda, USA. Currrently about thirty proton centres are either in operation or in construction worldwide.
The global Hadron Therapy market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hadron Therapy market based on company, product type, end user and key regions.

This report studies the global market size of Hadron Therapy in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hadron Therapy in these regions.
This research report categorizes the global Hadron Therapy market by top players/brands, region, type and end user. This report also studies the global Hadron Therapy market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Koninklijke Philips N.V.
Advanced Oncotherapy
Varian Medical Systems
Optivus Proton Therapy
Hitachi, Ltd.
Mevion Medical Systems
ProTom International
Mitsubishi Electric Corporation
Sumitomo Corporation
ProNova Solutions, LLC

Market size by Product
Electron Beam
Proton Beam
Neutron Beam
Carbon Ion Beam
Alpha Particle Beam
Beta Particle Beam
Market size by End User
Pediatric Cancer
Bone and Soft Tissue Cancer
Prostate Cancer
Lung Cancer
Liver Cancer
Eye Cancer
Head & Neck Cancer
Others Applications (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Hadron Therapy market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Hadron Therapy market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Hadron Therapy companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Hadron Therapy submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Hadron Therapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hadron Therapy market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.